Pure Global AI
NCT06261957Not yet recruiting

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma

A Randomized, Double-blind, Parallel Group, Multi-center Study to Evaluate the Long-term Safety of Salbutamol Rescue Medication When Administered Via Metered Dose Inhalers Containing the Propellant HFA-152a or Reference HFA-134a
GlaxoSmithKlinePhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Asthma
Drug/Device/Intervention
Salbutamol HFA-134a
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
GlaxoSmithKline
Location
Aventura,Clearwater,Edgewater,Miami,Winter Park,Rincon,Louisville,Owensboro,Minneapolis,Olive Branch,Columbia,Jersey City,Riverdale,Brooklyn,Asheville,Cincinnati,Dublin,Medford,DuBois,Philadelphia,Pit, Argentina,Canada,France,Greece,Italy,Panama,Poland,United Kingdom,United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Apr 19, 2024
End date
Apr 25, 2025
Enrollment
420 participants
Primary outcome

Number of participants with Adverse Events (AEs)

Summary

The goal of this study is to assess and compare the safety and tolerability of salbutamol
 administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane
 (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above
 with asthma.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06261957
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06261957 through Pure Global AI's free database. This Phase 3 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Asthma. Target enrollment is 420 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.